Mankind Pharma Limited (NSE: MANKIND)

Mankind Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	11,926	3,820	3,048	3,025	1,672	2,261
Short-Term Investments	35,342	7,464	1,413	1,023	5,311	1,938
Trading Asset Securities	-	22,581	10,755	8,745	13,062	6,650
Cash & Short-Term Investments	47,267	33,865	15,216	12,793	20,045	10,849
Cash Growth	103.22%	122.56%	18.94%	-36.18%	84.76%	58.55%
Accounts Receivable	12,719	8,483	5,764	3,882	3,306	5,311
Other Receivables	-	438.13	321.02	347.23	698.18	407.12
Receivables	12,754	8,950	6,102	4,241	4,188	6,063
Inventory	16,789	15,535	14,985	17,602	11,835	8,991
Prepaid Expenses	-	603.9	331.6	1,360	369.43	94.98
Other Current Assets	8,557	6,729	6,645	8,072	2,628	2,224
Total Current Assets	85,368	65,682	43,279	44,068	39,066	28,222
Property, Plant & Equipment	31,405	31,387	30,170	23,896	19,917	18,646
Long-Term Investments	3,223	3,111	3,578	2,404	2,097	1,644
Goodwill	200.2	200.23	200.23	204.42	204.42	204.42
Other Intangible Assets	16,199	16,630	17,584	18,742	187.62	259.47
Long-Term Deferred Tax Assets	953.5	803.98	297.77	392.86	490.11	479.39
Other Long-Term Assets	2,475	1,818	2,046	1,770	1,763	1,276
Total Assets	139,823	119,633	97,154	91,477	63,726	50,733
Accounts Payable	15,186	11,030	10,082	10,764	6,670	7,451
Accrued Expenses	-	2,228	1,710	2,598	1,287	877.69
Short-Term Debt	-	1,515	1,150	8,052	1,973	468.55
Current Portion of Long-Term Debt	4,513	196.96	244.68	242.47	185.02	244.41
Current Portion of Leases	36.9	34.23	25.57	20.57	16.22	11.4
Current Income Taxes Payable	1,125	463.79	462.56	150.9	110.85	656.22
Current Unearned Revenue	-	1,859	1,662	1,394	148.34	43.14
Other Current Liabilities	8,075	3,871	3,294	3,013	3,144	2,755
Total Current Liabilities	28,935	21,197	18,631	26,235	13,534	12,507
Long-Term Debt	206.7	248.68	231.47	491.94	576.7	581.93
Long-Term Leases	64.3	77.14	51.78	29.9	45.11	28.28
Long-Term Unearned Revenue	255.1	229.62	254.95	201.54	78.87	177.87
Long-Term Deferred Tax Liabilities	1,093	890.69	773.12	556.21	130.32	81.67
Other Long-Term Liabilities	-	-	-	-	10	10
Total Liabilities	31,930	23,875	20,922	28,314	15,097	14,017
Common Stock	400.6	400.59	400.59	400.59	400.59	400.59
Additional Paid-In Capital	493.9	421.17	421.17	421.17	421.17	421.17
Retained Earnings	113,448	101,566	82,499	69,729	55,413	43,032
Comprehensive Income & Other	-8,695	-8,757	-8,969	-8,999	-9,014	-9,001
Total Common Equity	105,648	93,631	74,352	61,552	47,220	34,853
Minority Interest	2,245	2,127	1,881	1,611	1,409	1,863
Shareholders' Equity	107,893	95,758	76,233	63,163	48,629	36,716
Total Liabilities & Equity	139,823	119,633	97,154	91,477	63,726	50,733
Total Debt	4,821	2,072	1,704	8,836	2,796	1,335
Net Cash (Debt)	42,447	31,793	13,512	3,957	17,249	9,515
Net Cash Growth	97.75%	135.29%	241.51%	-77.06%	81.29%	129.80%
Net Cash Per Share	105.78	79.25	33.73	9.88	43.06	23.75
Filing Date Shares Outstanding	400.6	400.64	400.59	400.59	400.59	400.59
Total Common Shares Outstanding	400.6	400.59	400.59	400.59	400.59	400.59
Working Capital	56,433	44,485	24,647	17,834	25,532	15,715
Book Value Per Share	263.72	233.73	185.61	153.65	117.88	87.00
Tangible Book Value	89,249	76,800	56,568	42,606	46,828	34,389
Tangible Book Value Per Share	222.79	191.72	141.21	106.36	116.90	85.85
Land	-	3,530	3,528	2,435	2,414	2,418
Buildings	-	12,487	10,460	5,863	5,750	5,555
Machinery	-	21,504	17,352	13,921	11,846	10,467
Construction In Progress	-	2,071	4,932	6,699	3,716	3,133
Leasehold Improvements	-	88.68	88.74	64.47	60.1	49.77

Source: S&P Capital IQ. Standard template. Financial Sources.